Summary
The total and unbound plasma concentrations of phenprocoumon and the prothrombin complex activity were determined in 51 patients on phenprocoumon.
A 7-fold difference in the dosing rate (10–70 µg/kg/day) was required to maintain the prothrombin complex activity at 11–30% of normal. The variation in dosing requirement was mainly due to inter-individual differences in the intrinsic clearance of phenprocoumon and only to a minor degree to differences in sensitivity to it.
On average patients with myocardial infarction required only 2/3 of the daily dose of phenprocoumon of post cardiac surgery patients and patients with thrombosis and emboli. That difference appeared to be due to higher clearance in surgical patients and to greater resistance to phenprocoumon in patients with thrombosis and emboli. The total clearance in patients varied approximately 5-fold. It was better predicted by the interindividual intrinsic clearance (r=0.84) than by the unbound fraction (r=0.15).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aggeler PG, O'Reilly RA (1966) The pharmacological basis of oral anticoagulant therapy. Thromb Diath Haemorrh 21 [Suppl]: 227–256
Breckenridge A, Orme MLE (1973) Measurement of plasma warfarin concentrations in clinical practice: In: Davies DS, Prichard BNC (eds) Biological effects of drugs in relation to their plasma concentration. Macmillan London, pp 145–154
Coon WW, Willis III PW (1970) Some aspects of the pharmacology of oral anticoagulants. Clin Pharmacol Ther 11: 312–336
Gugler R, Dengler HJ (1973) Arzneimittelinteraktionen mit oralen Antikoagulantien vom Cumarintyp. Klin Wochenschr 51: 1081–1090
Heni N, Glogner P (1973) Pharmacokinetics of phenprocoumon in man investigated using a gas chromatographic method of drug analysis. Naunyn Schmiedebergs Arch Pharmacol 293: 183–186
Husted S, Andreasen F (1977) Individual variation in the response to phenprocoumoun. Eur J Clin Pharmacol 11: 351–358
Jähnchen E, Meinertz T, Gilfrich HJ, Groth U, Martini A (1976) The enantionmers of phenprocoumon: Pharmacodynamic and pharmacokinetic studies. Clin Pharmacol Ther 20: 342–349
Jähnchen E, Meinertz T (1977) Pharmacokinetic aspects of overdosage and intoxication with oral anticoagulant drugs. Arzneimittelforsch (Drug Res) 27: 1849–1856
Øie S, Huang J-D (1983) Binding: Should free drug levels be measured. In: Breimer DD, Speiser P (eds) Topics in pharmaceutical sciences 1983. Elsevier, Amsterdam, pp 43–62
Quick AJ (1938) The nature of bleeding in jaundice. J Am Med Ass 110: 1658–1662
Routledge PA, Chapman PH, Davies DM, Rawlins MD (1979) Pharmacokinetics and pharmacodynamics of warfarin at steady-state. Br J Clin Pharmacol 8: 243–246
Schmucker DL (1985) Aging and drug disposition: An update. Pharmacol Rev 37: 133–148
Seiler K, Duckert F (1968) Properties of 3-(1-phenyl-propyl)-4-oxycoumarin (Marcumar) in the plasma when tested in normal cases and under the influence of drugs. Thromb Diath Haemorrh 19: 389–396
Seller E, Frecker R, Rohach M (1983) Drug metabolism in the elderly: Confounding of age, smoking, and ethanol effects. Drug Metab Rev 14: 225–250
Wilkinson GR, Shand DG (1975) A physiologic approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Yacobi A, Udall J, Levy G (1976) Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 19: 552–558
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Trenk, D., Althen, H., Jähnchen, E. et al. Factors responsible for interindividual differences in the dose requirement of phenprocoumon. Eur J Clin Pharmacol 33, 49–54 (1987). https://doi.org/10.1007/BF00610379
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00610379